Tango Therapeutics (TNGX) Payables (2020 - 2026)

Tango Therapeutics' Payables history runs 7 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Payables fell 24.98% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 24.98% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 26.17% from the prior year.
• Payables rose to $2.4 million in Q1 2026 per TNGX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Payables topped out at $6.3 million in Q3 2022 and bottomed at $1.1 million in Q2 2024.
• The 5-year median for Payables is $2.8 million (2023), against an average of $3.2 million.
• Across the five-year window, Payables soared 6342.41% in 2022 and sank 77.84% in 2024, its largest moves.
• Year by year, Payables stood at $4.5 million in 2022, then plunged by 37.46% to $2.8 million in 2023, then slumped by 42.51% to $1.6 million in 2024, then slipped by 26.17% to $1.2 million in 2025, then jumped by 105.58% to $2.4 million in 2026.
• Per Business Quant, the three latest TNGX Payables figures stand at $2.4 million (Q1 2026), $1.2 million (Q4 2025), and $2.2 million (Q3 2025).